Experimental drug for Post-COVID POTS study halted early
NCT ID NCT05918978
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety of efgartigimod in adults with post-COVID postural orthostatic tachycardia syndrome (POTS), a condition causing rapid heart rate and dizziness upon standing. The trial was an open-label extension for people who completed a previous study. However, the study was terminated early, so only limited safety information is available from the 33 participants enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- efgartigimod
- What this could lead to
- If successful, this could point toward a treatment option for post-COVID POTS, a condition with few approved therapies.
- What could go wrong
- The study was terminated early with only 33 participants, so we have very limited data on safety and effectiveness. It is still unclear if efgartigimod helps POTS symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-COVID POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Apex Trials Group
Fort Worth, Texas, 76104, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
Metrodora Institute
West Valley City, Utah, 84119, United States
-
North Shore University HealthSystem
Glenview, Illinois, 60026, United States
-
Pioneer Clinical Research
Rosharon, Texas, 77583, United States
-
Standford Movement Disorder Center
Palo Alto, California, 94304, United States
-
UC Sand Diego Sulpizio Cardiovascular Center
La Jolla, California, 92037, United States
-
University Hospitals, Neurology Clinical Trials
Cleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.